Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Mastrolonardo EV, Nunes KL, Llerena P, Nikitina A, Sobol A, Scott ER, Tuluc M, Davitt CJH, Scher J, Tekumalla S, Mann D, Henao C, Jegede V, Gargano S, Harshyne LA, Alnemri A, Tyshevich A, Kushnarev V, Chasse M, Sookiasian D, Axelrod R, Zhan T, Leiby BE, Old M, Seim N, Mahoney MG, Martinez-Outschoorn U, Cognetti DM, Curry JM, Prendergast GC, Argiris A, South AP, Linnenbach AJ, Johnson JM, Luginbuhl AJ. Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 02 03; 31(3):515-528.
-
Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, Ghebre RG, Gressel GM, Lesnock JL, Meyer LA, Moore KN, O'Cearbhaill RE, Olawaiye AB, Salani R, Sparacio D, van Driel WJ, Tew WP. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. J Clin Oncol. 2025 03; 43(7):868-891.
-
Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J Clin Oncol. 2025 03 20; 43(9):1113-1122.
-
Mandloi S, Gargano SM, Duffy AN, Benedict PA, Shing SR, Kahn C, Hannikainen P, Pineda-Reyes JP, Bray D, Toskala EM, Rabinowitz M, Rosen M, Farrell C, Evans JJ, Nyquist GG. The Presence of Pigment Incontinence in Sinonasal Mucosal Melanoma. Laryngoscope. 2025 04; 135(4):1321-1325.
-
Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, Balbaloglu H, Balint-Lahat N, Banys-Paluchowski M, Barrio AV, Benson J, Bese N, Boughey JC, Boyle MK, Diego EJ, Eden C, Eller R, Goldschmidt M, Hlavin C, Heidinger M, Jelinska J, Karadeniz Cakmak G, Kesmodel SB, King TA, Kuerer HM, Loesch J, Milardi F, Murawa D, Moo TA, Menes TS, Passeri D, Pastoriza JM, Perhavec A, Pislar N, Polidorio N, Rami A, Ryu JM, Schulz A, Sevilimedu V, Ugurlu MU, Uras C, van Hemert A, Wong SM, Yoo TR, Zhang JQ, Karanlik H, Cabioglu N, Peeters MV, Morrow M, Weber WP. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. J Clin Oncol. 2025 03; 43(7):810-820.
-
Vitello DJ, Shah D, Wells A, Masnyk L, Cox M, Janczewski LM, Abad J, Dawravoo K, D'Souza A, Suh G, Bayer R, Cristofanilli M, Bentrem D, Liu Y, Zhang H, Santana-Santos L, Jennings LJ, Zhang Q, Chawla A. Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy. Ann Surg. 2026 07 01; 284(1):99-107.
-
Rencuzogullari A, Karahan SN, Selcukbiricik F, Lacin S, Taskin OC, Saka B, Karahacioglu D, Gurses B, Ozoran E, Uymaz DS, Ozata IH, Saglam S, Bugra D, Balik E. The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy. J Surg Oncol. 2025 Mar; 131(3):417-426.
-
Nadeem MS, Ali U, Khan A, Wajid I, Riaz O, Azeem MT. Response of various histological types of locally advanced rectal cancer to neoadjuvant multimodality therapy. J Pak Med Assoc. 2024 Jul; 74(7):1240-1244.
-
Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, Barrio AV, van den Bruele AB, Cabioglu N, Sevilimedu V, Rosenberger LH, Hwang ES, Ingham A, Papassotiropoulos B, Nguyen-Str?uli BD, Kurzeder C, Aybar DD, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Karanlik H, Dedes KJ, Romics L, Banys-Paluchowski M, Muslumanoglu M, Perez MDRC, D?az MC, Heidinger M, Fehr MK, Reinisch M, Tukenmez M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Paulinelli RR, Zarhi SS, Kuemmel S, Bruzas S, di Lascio S, Parissenti TK, Hoskin TL, G?th U, Ovalle V, Tausch C, Kuerer HM, Caudle AS, Boileau JF, Boughey JC, K?hn T, Morrow M, Weber WP. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy. JAMA Oncol. 2024 06 01; 10(6):793-798.
-
Alnemri AE, Tekumalla S, Moroco AE, Vathiotis I, Tuluc M, Gargano S, Zhan T, Cognetti DM, Curry JM, Argiris A, Linnenbach A, South AP, Harshyne LA, Johnson JM, Luginbuhl AJ. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma. Cancer Med. 2024 06; 13(11):e7370.